View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
January 28, 2013

Algeta to evaluate targeted thorium conjugate for cancer therapy

Norway-based Algeta has commenced a new oncology research programme to evaluate the potential of a targeted thorium conjugate (TTC).

Norway-based Algeta has commenced a new oncology research programme to evaluate the potential of a targeted thorium conjugate (TTC).

The TTC is a combination of Algeta’s thorium-227 alpha-pharmaceutical payload and Immunomedics’ anti-CD22 monoclonal antibody (epratuzumab), a well-validated target for hematological cancers.

Algeta executive vice president and chief technology officer Thomas Ramdahl said thorium-227 payload has a broad utility and has better potential to kill cancer cells compared to other therapeutic payloads.

"This collaboration brings together Algeta, the global leader in alpha-pharmaceuticals and Immunomedics, a pioneer in antibody products and technologies," Ramdahl said.

"A TTC based on a well-validated antibody such as epratuzumab is an exciting prospect as we work to achieve our goal of generating a clinical candidate from the TTC platform in 2014."

According to the deal, Immunomedics will provide clinical-grade antibody to Algeta for the evaluation of potential of a TTC.

Algeta will fund all preclinical and clinical development expenses till the end of Phase I testing, after which the companies shall discuss licensing terms, based on certain parametres.

Immunomedics will earn a signature fee, an antibody delivery milestone and payments for cGMP antibody manufacture from Algeta in the first year.

Further details of the deal have not been revealed.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU